INTRODUCTION
Mammalian cell death proceeds through a highly regulated genetic program termed apoptosis that is heavily dependent on the mitochondria (Danial and Korsmeyer, 2004) . Multiple apoptotic signals culminate in permeabilizing the mitochondrial outer membrane (MOM), resulting in the release of apoptogenic factors including cytochrome c and SMAC (Wang, 2001) . Once released, cytochrome c activates Apaf-1 to assist the activation of caspases that cleave cellular proteins and thereby contribute to the morphological and biochemical changes associated with apoptosis. The permeabilization of the MOM not only couples the mitochondria to the activation of caspases but also initiates caspase-independent mitochondrial dysfunction ). The BCL-2 family proteins control a crucial checkpoint of apoptosis at the mitochondria (Cory and Adams, 2002; Korsmeyer et al., 2000) . Multidomain proapoptotic BAX and BAK are essential effectors responsible for the permeabilization of the MOM, whereas anti-apoptotic BCL-2, BCL-X L , and MCL-1 preserve mitochondrial integrity and prevent cytochrome c efflux triggered by apoptotic stimuli. The third BCL-2 subfamily of proteins, BH3-only molecules (BH3s), promotes apoptosis by either activating BAX/BAK or inactivating BCL-2/BCL-X L /MCL-1 (Certo et al., 2006; Cheng et al., 2001; Kim et al., 2006; Kuwana et al., 2005; Letai et al., 2002; Wei et al., 2000; Wei et al., 2001) . Upon apoptosis, the ''activator'' BH3s, including truncated BID (tBID), BIM, and PUMA, activate BAX and BAK to mediate cytochrome c efflux, leading to caspase activation Desagher et al., 1999; Kim et al., 2006; Wei et al., 2000 Wei et al., , 2001 . Conversely, the antiapoptotic BCL-2, BCL-X L , and MCL-1 sequester activator BH3s into inert complexes, thus preventing BAX/BAK activation Kim et al., 2006) . The remaining BH3s including BAD, NOXA, BMF, HRK, and BIK/BLK do not activate BAX/BAK directly but instead prevent the anti-apoptotic BCL-2 members from sequestering the activator BH3s (Certo et al., 2006; Kim et al., 2006; Kuwana et al., 2005; Letai et al., 2002) . Although it was proposed that activation of BAX and BAK occurred by default as long as all the anti-apoptotic BCL-2 proteins were neutralized by BH3s (Willis et al., 2007) , the liposome studies clearly recapitulate the direct activation model in which tBID protein or BH3 domain peptides derived from BID or BIM induced BAX oligomerization and membrane permeabilization (Gavathiotis et al., 2008; Kuwana et al., 2002; Walensky et al., 2006) . In addition, the temporal sequence of BAX activation by tBID was nicely demonstrated recently by a fluorescence resonance energy transfer (FRET)-based liposomal study (Lovell et al., 2008) .
While BAK and BAX are the essential effectors of mitochondrial apoptosis, their proapoptotic activity is tightly kept in check Lindsten et al., 2000; Wei et al., 2001) . BAX exists in the cytosol as a monomer, with its C-terminal a9 helix occupying the dimerization pocket formed by BH1-3 domains (Suzuki et al., 2000) . This autoinhibited BAX monomer may be further stabilized by associated proteins (Reed, 2006) . By contrast, the C-terminal a9 helix of BAK is constitutively inserted in the MOM, and its activity is inhibited by a mammalian restricted VDAC isoform, VDAC2, which occupies the dimerization pocket of BAK to restrict BAK in the monomeric inactive conformation Ren et al., 2009; Wei et al., 2000) . Upon apoptosis, activator BH3s induce conformational changes of BAX to promote the targeting and homooligomerization of BAX at the MOM, and disrupt BAK-VDAC2 interaction to enable homo-oligomerization of BAK, leading to the efflux of apoptogenic factors Desagher et al., 1999; Kim et al., 2006; Ren et al., 2009; Wei et al., 2000) . Therefore, the proapoptotic activity of BAX and BAK is triggered by BH3s, whose activity is in turn regulated either transcriptionally or posttranslationally by upstream death signaling cascades (Danial and Korsmeyer, 2004; Korsmeyer et al., 2000) . By analogy, BH3s function as death ligands that allosterically regulate the mitochondrial death receptor BAX/BAK .
Conformational changes and homo-oligomerization are two critical events associated with the activation of BAX/BAK by BH3s Reed, 2006) . However, the underlying mechanisms remain unsettled. It is especially complex for BAX due to its change in the subcellular localization during apoptosis (Wolter et al., 1997) . The N-terminal exposure of BAX is a commonly used marker for its activation of which the molecular basis is obscure (Desagher et al., 1999; Nechushtan et al., 1999) . Although it was proposed that the intramolecular interaction between the N-and C-terminal regions of BAX might somehow regulate its activation (Goping et al., 1998; Nechushtan et al., 1999; Schinzel et al., 2004) , direct experimental data supporting this model are missing. Interestingly, our recent study demonstrated that an interaction site involving the a1 and a6 helixes of BAX and the BH3 domain of BIM is required for BAX activation (Gavathiotis et al., 2008) . The a1 helix of BAX was also implicated in its interaction with BID and PUMA (Cartron et al., 2004) . However, it is unknown how this interaction contributes to BAX activation. BAK was reported to expose its BH3 domain to form dimers via BH3-groove interactions (Dewson et al., 2008) . Unfortunately, this study did not examine higherordered BAK oligomers that are more functionally relevant since BAX tetramers, but not dimers, could form pores large enough for cytochrome c passage . To address these questions, we performed structural functional analyses to dissect the molecular mechanisms by which BH3s activate BAX/BAK.
We demonstrate that activation of BAX can be dissected into two sequential steps, mitochondrial targeting and homo-oligomerization, both of which require activator BH3s. The a1 helix of BAX stabilizes the binding of the a9 helix to the dimerization pocket, which in turn controls the mitochondrial targeting of BAX. Thus, tBID, BIM, and PUMA initiate the activation process of BAX by attacking the a1 helix, resulting in the N-terminal exposure of BAX and secondary disengagement of the a9 helix that becomes available for mitochondrial targeting. tBID, BIM, and PUMA remain associated with the N-terminally exposed BAX to drive the homo-oligomerization of mitochondrially localized BAX. Our data reveal dynamic interactions between activator BH3s and BAX, which help explain the previous difficulty in detecting these interactions. BAK, an integral mitochondrial membrane protein, constitutively exposes its a1 helix and requires activator BH3s to trigger its homo-oligomerization. The BH1 and BH3 domains are required for the assembly of higher-ordered BAX or BAK oligomers, which is essential for the proapoptotic activity of BAX or BAK. Moreover, ER stress induces BIM and PUMA to activate BAX/BAK at the mitochondria, exemplifying how activator BH3s interconnect upstream death signaling cascades with downstream BAX/BAK-dependent mitochondrial death program. All together, our study supports the direct engagement of activator BH3s in activating BAX/BAK-dependent mitochondrial apoptosis.
RESULTS
Previous mutagenesis studies of BAX and BAK often generate conflicting results due to overexpression of BAX/BAK mutants in cells containing wild-type (WT) BAX/BAK, which likely assess their function as BH3-like death ligands that could activate endogenous BAX/BAK (Chittenden et al., 1995; Simonen et al., 1997; Wang et al., 1998) . To fully address the role of BAX and BAK as mitochondrial death receptors, we reconstituted mutants of BAX or BAK into Bax/Bak double knockout (DKO) mouse embryonic fibroblasts (MEFs) to a physiological level similar to WT cells and examined the ability of each mutant to restore the apoptotic sensitivity of death-resistant DKO cells (see Figure S1 available online).
Mitochondrial Targeting and Homo-oligomerization Are Two Separable, Essential Steps of BAX Activation Although BAX contains a conserved, putative transmembrane domain at the C-terminal a9 helix (Wolter et al., 1997) , it was reported that its N terminus also bears a mitochondrial targeting signal (Cartron et al., 2003) . To determine whether the C-terminal transmembrane domain is required for the mitochondrial targeting and proapoptotic activity of BAX, GFP-BAX or GFP-BAXDC (BAX mutant with deletion of the C-terminal transmembrane domain) was reconstituted into DKO cells. In accordance with BAX, GFP-BAX restored the apoptotic sensitivity of DKO cells and translocated from cytosol to mitochondria in response to various intrinsic death signals (Figures 1A and 1C and data not shown) . On the contrary, GFP-BAXDC remained in the cytosol upon death stimuli, and BAXDC failed to induce apoptosis, supporting the essential role of a9 helix for both mitochondrial targeting and death induction ( Figures  1A and 1C) .
The S184V mutation at the a9 helix of BAX constitutively targeted BAX to mitochondria, which is consistent with a previous report (Nechushtan et al., 1999) (Figure 1B ). Remarkably, BAX S184V did not spontaneously induce apoptosis in the absence of death signals ( Figure 1C ). DKO cells reconstituted with BAX S184V did die faster than those expressing WT BAX ( Figure 1D ), consistent with the notion that BAX S184V has bypassed the activation process required for mitochondrial targeting. This might help explain why Bax-deficient cells (BAK-dependent apoptosis) died faster than Bak-deficient cells (BAX-dependent apoptosis) ( Figure S2 ). Interestingly, L63E mutation at the BH3 domain also rendered BAX localized at the mitochondria, but it totally abolished the proapoptotic activity ( Figures 1B and 1C) . To determine the molecular basis underlying the functional differences between these two mitochondria-targeted BAX mutants, we examined whether they differ in the ability to undergo conformational changes. The N-terminal BAX epitope recognized by the 6A7 antibody (aa residues 12-24) becomes exposed after an apoptotic stimulus Nechushtan et al., 1999) . Thus, anti-6A7 antibody could only immunoprecipitate BAX from cells following DNA damage, but not from viable cells using CHAPS buffer ( Figure 1E ). It was reported that NP-40 and Triton X-100, but not CHAPS, could induce the conformational changes of BAX . Surprisingly, both L63E and S184V mutants of BAX have already exposed their N termini even in the absence of apoptotic stimuli ( Figure 1E ). These data suggest that the N-terminal exposure indicates mitochondrial targeting but not full activation of BAX. We next performed gel filtration assays to assess the formation of BAX homo-oligomers triggered by tBID. Like WT BAX, BAX S184V was eluted as a monomer (molecular weight 20 kD) before activation and formed higher-ordered oligomers in response to tBID ( Figure 1F ). By contrast, BAX L63E failed to undergo homo-oligomerization and was eluted around 50-60 kD range, irrespective of tBID treatment ( Figure 1F ). It is possible that BAX L63E formed dimer, or associated with other proteins or detergent micelles, which accounts for its elution at almost twice of its molecular weight. Nevertheless, these findings clearly demonstrate the importance of BH3 domain for the homo-oligomerization and thereby the proapoptotic activity of BAX.
The N-Terminal Exposure of BAX Correlates with Mitochondrial Targeting Rather Than Homo-oligomerization To further investigate the importance of BAX homo-oligomerization, we performed extensive mutagenesis and identified two additional BAX mutants that failed to undergo homo-oligomerization. BH1 (G108E) and BH3 (G67R) domain mutants failed to form higher-ordered oligomers detected by gel filtration in response to tBID ( Figure 2A ). In addition, HA-tagged BAX G67R or G108E was unable to coprecipitate nontagged corresponding mutant by anti-HA immunoprecipitation (IP) ( Figure S3 ). Accordingly, these two mutants were unable to rescue the apoptotic defect of DKO cells ( Figure 2B ). The S184V substitution was introduced into these BAX mutants to enforce mitochondrial localization. These mutants remained inactive in triggering apoptosis upon death signals ( Figure 2C ). GFP-BAX G108E/S184V targeted at the mitochondria constitutively, whereas GFP-BAX G67R/S184V only exhibited partial mitochondrial localization ( Figure 2D ). Since our initial study suggests that the N-terminal exposure of BAX likely reflects mitochondrial targeting, we next tested whether these two double mutants could be pulled down by the 6A7 antibody. Indeed, the N terminus of BAX G108E/S184V was readily exposed in the absence of apoptotic stimuli, whereas that of BAX G67R/ S184V was partially exposed ( Figure 2E ). By analogy to BAX L63E, the mitochondria-targeted BAX G108E/S184V could not be activated by tBID to undergo homo-oligomerization detected by protein crosslinking and thereby failed to induce apoptosis (Figures 2C and 2F) . We also tested a previously reported BAX P168A mutant that was defective in mitochondrial targeting (Schinzel et al., 2004) . This mutant, when stably reconstituted in DKO cells, could not be immunoprecipitated by the 6A7 antibody ( Figure S4 ). Of note, it was previously reported that the N terminus of this mutant was exposed when it was overexpressed in HeLa cells that contain WT BAX/BAK (Schinzel et al., 2004) . Collectively, the N-terminal exposure of BAX is the conformational change associated with mitochondrial targeting rather than homo-oligomerization. More importantly, our data indicate that mitochondrial targeting and homo-oligomerization are two separable, distinct steps of BAX activation. Homo-oligomerization of BAX is apparently not required for BAX to translocate to mitochondria.
The BH1 and BH3 Domains of BAX Are Required for Its Activation Although both BAX G67R and G108E mutants failed to undergo homo-oligomerization driven by tBID, it remains possible that they have defects even in the earlier step of conformational changes. Indeed, both mutants failed to translocate to mitochondria following intrinsic death signals and were unable to expose their N-terminal epitope in response to DNA damage or tBID ( Figures 3A and 3B ), indicating that they have defects in the first step of BAX activation. In addition to visualizing mitochondrial targeting, we performed alkaline extraction to quantify the percentage of WT or mutant BAX integrating into the MOM (Goping et al., 1998) . BAX was loosely associated with mitochondria and could be extracted by alkali ( Figure 3C ). Once activated by tBID, BAX inserted into the MOM and became resistant to alkaline extraction ( Figure 3C ). By contrast, both G67R and G108E mutants were still sensitive to alkaline extraction, indicating that they failed to insert into the MOM upon tBID treatment. Similar to tBID, BIM and PUMA also directly activated BAX to induce its mitochondrial insertion ( Figure 3D ). Collectively, intact BH1 and BH3 domains are essential for the activation of BAX by activator BH3s.
The a1 Helix of BAX Controls the Engagement of the a9 Helix into the Dimerization Pocket The observation that the N-terminal exposure of BAX initiates its activation and dictates mitochondrial targeting prompted us to explore how the N-terminal exposure of BAX regulates its mitochondrial targeting. Given that the a9 helix of BAX occupies its hydrophobic pocket formed by BH1-3 domains to prevent mitochondrial targeting and dimerization (Suzuki et al., 2000) , one testable thesis is that the N terminus stabilizes the engagement of the a9 helix in the hydrophobic pocket to keep BAX in an inactive conformation. To test this hypothesis, we developed an in vitro system to recapitulate the intramolecular interaction between the hydrophobic pocket of BAX and the C-terminal a9 transmembrane domain (TM). We found that HA-tagged BAXDC could coprecipitate the a9 helix of BAX fused to the C terminus of GST using anti-HA IP in the presence of CHAPS ( Figure 4A ). S184V mutation within the a9 helix abolished its association
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Stepwise Activation of BAX/BAK by tBID/BIM/PUMA with BAXDC, suggesting that the a9 helix of BAX S184V no longer stays in the pocket and becomes available to insert into the MOM. Importantly, deletion of the a1 helix in BAXDC (BAXDNDC) disrupted the interaction between the a9 helix and the hydrophobic pocket, indicating that the N-terminal a1 helix stabilizes the binding of the a9 helix to the pocket ( Figure 4A ). These data are supported by a previous report demonstrating that N-terminally deleted BAX could target to mitochondria constitutively (Goping et al., 1998) .
The aforementioned findings led to our next hypothesisexposure of the a1 helix results in the disengagement of the a9 helix and subsequent mitochondrial translocation. To test this hypothesis, we developed another in vitro system to detect the intramolecular interaction between the a1 helix of BAX and BAXDN with deletion of the N-terminal 37 amino acid residues. HA-tagged a1 helix of BAX coprecipitated BAXDN using anti-HA IP in the presence of CHAPS ( Figure 4B ). Of note, NP-40 disrupted this interaction, consistent with the notion that NP-40 induces the conformational changes of BAX ( Figure S5 ). The NMR structure of BAX reveals that the a2 helix (BH3 domain) of BAX is in close proximity to its a1 helix (Suzuki et al., 2000) . This prompted us to investigate whether the mitochondria-targeted BAX a2 helix L63E mutant might destabilize the interaction between the a1 helix of BAX and BAXDN, resulting in secondary disengagement of the a9 helix. Indeed, the a1 helix failed to interact with BAXDN containing L63E mutation ( Figure 4B ). By contrast, another BH3 domain mutation G67R had no effect on this interaction, and BAX G67R was cytosolic ( Figure 4B ). These findings provide a mechanistic basis explaining how a mutation at the BH3 domain affects mitochondrial targeting. Moreover, S184V mutation abrogated the interaction between the a1 helix and BAXDN, consistent with the observation that BAX S184V readily exposed its N terminus ( Figure 4C ). (A) The a1 helix of BAX keeps the a9 helix engaged in the dimerization pocket. Radiolabeled IVTT HA-tagged BAXDC or HA-tagged BAXDNDC in combination with GST-a9 or GST-a9 S184V were subjected to anti-HA IP in 1% CHAPS. Immunoprecipitates and pre-IP input were analyzed by Nu-PAGE and autoradiography. Asterisk denotes the degradation products. (B) The L63E mutation in BAX disrupts the binding of the a1 helix to the rest of the protein, resulting in N-terminal exposure and mitochondrial targeting. Radiolabeled IVTT HA 3 -tagged BAX a1 helix in combination with BAXDN WT, L63E, or G67R was subjected to anti-HA IP in 1% CHAPS. Immunoprecipitates and pre-IP input were analyzed by Nu-PAGE and autoradiography. (C) The S184V mutation in BAX destabilizes the binding of the a1 helix to the rest of the protein. Radiolabeled IVTT HA 3 -tagged BAX a1 helix in combination with BAXDN WT or S184V were subjected to anti-HA IP in 1% CHAPS. Immunoprecipitates and pre-IP input were analyzed by Nu-PAGE and autoradiography. (D) tBID, BIM, and PUMA bind to the a1 helix of BAX. Radiolabeled IVTT HA 3 -tagged BAX a1 helix in combination with tBID, BIM, or PUMA were subjected to anti-HA IP in 1% CHAPS. Immunoprecipitates and pre-IP input were analyzed by Nu-PAGE and autoradiography. (E) tBID, BIM, and PUMA, but not BAD, induce the N-terminal exposure of BAX and remain associated with the N-terminally exposed BAX. Radiolabeled IVTT BAX incubated with tBID, BIM, PUMA, or BAD were immunoprecipitated with the 6A7 antibody in 1% CHAPS. Immunoprecipitates and pre-IP input were analyzed by Nu-PAGE and autoradiography. (F) tBID, BIM, and PUMA induce the homo-oligomerization of BAX S184V. Mitochondria isolated from DKO MEFs reconstituted with BAX S184V were incubated with IVTT tBID, BIM, or PUMA for 30 min and then treated with BMH crosslinker. The BAX oligomers were detected by an anti-BAX immunoblot. (G) BH1 domain is required for N-terminally exposed BAX to interact with tBID. Radiolabeled IVTT BAX L63E or BAX L63E/G108E incubated with tBID were immunoprecipitated with the 6A7 antibody in 1% CHAPS. Immunoprecipitates and pre-IP input were analyzed by Nu-PAGE and autoradiography.
Stepwise Activation of BAX/BAK by tBID/BIM/PUMA tBID, BIM, and PUMA Induce the N-Terminal Exposure of BAX and Remain Associated with the N-Terminally Exposed BAX through the BH1 Domain As the a1 helix of BAX controls the pivotal step of conformational changes, we next investigated whether activator BH3s initiate BAX activation by binding directly to the a1 helix of BAX. Indeed, HA-tagged a1 helix of BAX coprecipitated tBID, BIM, and PUMA, but not BAD or BMF in vitro ( Figure 4D and Figure S6 ). These findings are supported by our recently solved NMR structure of BAX complexed with BIM BH3 peptide in which the a1 and a6 helices of BAX were involved in the binding with BIM (Gavathiotis et al., 2008) . Furthermore, tBID, BIM, and PUMA, but not BAD or BMF, could directly induce the N-terminal exposure of BAX in vitro ( Figure 4E and Figure S7 ). Coincubation of BAX with tBID, BIM, and PUMA led to the exposure of a1 helix of BAX that could be immunoprecipitated by the 6A7 antibody ( Figure 4E ). Remarkably, tBID, BIM, and PUMA were coprecipitated with the N-terminally exposed BAX using the 6A7 antibody ( Figure 4E ). Since the a1 helix is the epitope recognized by the 6A7 antibody, the binding between BH3s and the a1 helix of BAX must be transient, otherwise activated BAX would not be pulled down by the 6A7 antibody. As BH3s remain associated with the N-terminally exposed BAX, they must bind to a region other than the a1 helix. The second interaction is probably essential for the subsequent activation of BAX to induce homo-oligomerization, since the N-terminal exposure of BAX only contributes to mitochondrial targeting. The N-terminally exposed BAX S184V mutant did not undergo homo-oligomerization until it was activated by tBID, BIM, and PUMA ( Figure 4F ). Of note, inactivator BH3s such as BAD or BMF failed to induced homo-oligomerization of BAX S184V mutant ( Figure S8 ). To identify the second interaction site between N-terminally exposed BAX and BH3s, we reason that the canonical dimerization pocket is the most likely candidate, since it is no longer blocked by the a9 helix and the BH1 domain has been demonstrated to mediate the interaction between BAX and BID (Wang et al., 1996) . Since BH1 domain mutant of BAX (G108E) failed to undergo N-terminal exposure triggered by BH3s, we introduced L63E mutation on top of G108E to bypass the first activation step. Indeed, BAX L63E/G108E mutant constitutively exposed its N terminus and targeted to the mitochondria (data not shown). Importantly, BAX L63E/G108E failed to coprecipitate tBID using the 6A7 antibody ( Figure 4G ). Furthermore, BAX G108E failed to interact with tBID in NP-40, which induced its N-terminal exposure ( Figure S9 ). Together, our data discover dynamic interactions between activator BH3s and BAX.
The BH1 and BH3 Domains Are Essential for the Assembly of Higher-Ordered BAK Oligomers and the Proapoptotic Activity of BAK To investigate the importance of BH1 and BH3 domains for the proapoptotic activity of BAK, W122A/G123E/R124A (BH1) and L75E (BH3) mutants of BAK were generated. These two mutants failed to form higher-ordered oligomers in response to tBID ( Figure 5A ). In addition, HA-tagged BH1 or BH3 mutant was unable to coprecipitate nontagged corresponding mutant by anti-HA IP ( Figure 5B ). Accordingly, they were unable to induce apoptosis following intrinsic death signals when they were reconstituted in DKO cells ( Figure 5C ). Of note, these two mutants localized at the mitochondria like WT BAK ( Figure 5D ). Similar to the N-terminally exposed BAX, the BH1 domain of BAK was involved in its binding to tBID ( Figure 5E ). Although the N-terminal exposure of human BAK following apoptotic signals was suggested by a conformation-specific antibody (Ab-1) using FACS analysis (Griffiths et al., 1999) , mutagenesis studies indicated that it neither correlated with dimerization nor was required for the proapoptotic activity (Dewson et al., 2008) . Intriguingly, the epitope recognized by Ab-1 is not clear, since it was generated using the C-terminal truncated human BAK protein, and Ab-1 could not detect mouse BAK even by immunoblots. The enhanced detection of BAK by Ab-1 or Ab-2 during apoptosis may represent a more global conformational change rather than a simple exposure of the a1 helix of BAK. To address the exposure of the a1 helix in mouse BAK, we performed IP using antibody specific for the a1 helix of BAK (NT), which immunoprecipitated comparable amounts of mouse BAK before or after tBID activation in MEFs ( Figure 5F ). Comparable amounts of BAK were immunoprecipitated before or after staurosporine treatment in two additional mouse cell lines, 4T1 (breast cancer) and N18 (neuroblastoma) ( Figure 5G ). These data suggest that the integral mitochondrial membrane protein BAK constitutively exposes its N-terminal a1 helix, reminiscent of mitochondrially translocated BAX.
Death Signals Initiated from ER Require Mitochondriabut Not ER-Localized BAK to Execute Apoptosis BAX and BAK not only control the mitochondrial gateway of apoptosis but also regulate ER calcium homeostasis (Scorrano et al., 2003; Zong et al., 2003) . Since BAK is an integral membrane protein that resides at both mitochondria and ER (Scorrano et al., 2003; Zong et al., 2003) , we generated BAK chimera proteins that were specifically targeted to ER or mitochondria to determine the contribution of ER calcium regulation to apoptosis controlled by BAK. The transmembrane domain of BAK was replaced by heterologous ER or mitochondrial targeting signals derived from cytochrome b5 and OMP25, respectively ( Figure 6A ) (Shirane and Nakayama, 2003; Zhu et al., 1996) . The restricted localization of BAKDC/Cb5 at ER and that of BAKDC/OMP25 at mitochondria were confirmed by fusing these chimera proteins with YFP ( Figure S10 ). The proapoptotic activity of these BAK mutants was assessed by reconstituting these BAK mutants in DKO cells. Interestingly, targeting of BAK to the mitochondria restored the apoptotic response of DKO cells not only to staurosporine (a general kinase inhibitor) and etoposide (DNA damage) but also to ER stress induced by tunicamycin and thapsigargin ( Figure 6B ). By (G) BAK constitutively exposes its N-terminal a1 helix. 4T1 or N18 cells before or after staurosporine treatment were lysed in 1% CHAPS and then immunoprecipitated with the a1 helix-specific anti-BAK antibody (NT). Immunoprecipitates and pre-IP input were analyzed by anti-BAK (G23) immunoblots.
Stepwise Activation of BAX/BAK by tBID/BIM/PUMA contrast, ER-targeted BAK failed to rescue the apoptotic defect of DKO cells even to ER stress ( Figure 6B ). The minor difference in activating apoptosis between WT BAK and BAKDC/OMP25 is likely due to the lower protein expression level of BAKDC/ OMP25, which was less stable ( Figure S1 ). These data clearly indicate that death signals emanated from ER also converge on mitochondrial BAK to execute apoptosis.
ER Stress Induces BIM and PUMA to Activate BAX/BAKDependent Mitochondrial Death Program
Since BAK needs to be activated by BH3s, we envision that activator BH3s must be induced by ER stress to provide the missing link that interconnects ER stress signaling and the BAX/BAK- dependent mitochondrial death program. Indeed, ER stress induced BIM and PUMA proteins ( Figure 6C ). Consequently, Bim or Puma single knockout cells were resistant to ER stress-induced apoptosis, and double deficiency of Bim and Puma provided further protection ( Figure 6D ). Importantly, ER stressinduced homo-oligomerization of BAX or BAK was blocked by the deficiency of Bim and Puma, supporting the thesis that BIM and PUMA are required to activate BAX/BAK upon ER stress ( Figures  6E and 6F) . Collectively, these findings exemplify the essence of BAX/BAK activation driven by activator BH3s in the context of normal cell death signaling cascades.
DISCUSSION
How the death effectors BAX and BAK are activated to trigger the mitochondria-dependent death program remains as one of the most vigorously debated topics in apoptosis research (Chipuk and Green, 2008; Youle and Strasser, 2008) . Here we propose a stepwise activation model of BAX and BAK driven by activator BH3s, tBID, BIM, and PUMA ( Figure 7 and Table S1 ). We demonstrated that the a1 helix of BAX stabilizes and thereby controls the engagement of the a9 helix in the dimerization pocket. tBID, BIM, and PUMA bind transiently to the a1 helix of BAX to unleash autoinhibition, which allows for the structural reorganization by exposing both N and C termini. The C-terminal transmembrane domain hence becomes available for insertion into the MOM. tBID, BIM, and PUMA remain associated with the N-terminally exposed BAX to drive the homo-oligomerization of mitochondrially localized BAX. BAK, an integral mitochondrial membrane protein, constitutively exposes its a1 helix and requires tBID, BIM, and PUMA to trigger its homo-oligomerization. The homo-oligomerization of BAX or BAK appears to involve the interaction between the BH3 domain of one molecule and the canonical dimerization pocket of the other, since mutations in either BH1 or BH3 domain abolish their homo-oligomerization, the same strategy utilized for the heterodimerization between BH3s and antiapoptotic BCL-2 members (Sattler et al., 1997; Walensky, 2006) . Previous mutagenesis studies often involve overexpression of mutant BAX or BAK in WT cells such that BH3 but not BH1 mutants were defective in triggering apoptosis (Chittenden et al., 1995; Simonen et al., 1997) . Recently, the importance of BH1 and BH3 domains for the homo-oligomerization of BAX and BAK was reported (Dewson et al., 2008; George et al., 2007) .
The ''indirect'' activation model of BAX/BAK is proposed based on the lack of strong and stable interaction between BH3s and BAX/BAK (Willis et al., 2007) . Our study reveals the dynamic nature of the interaction between BH3s and BAX, because the conformational changes of BAX apparently involve a continuous, step-by-step structural reorganization, which helps explain the difficulty in detecting these interactions. BH3s first attack the a1 helix of BAX and then interact with BH1 domain once the N and C termini are exposed. Importantly, BH3s stay associated with BAX in the ''transition state'' conformation. It is remarkable that stable interaction between BH3s and BAX, at close to 1:1 stoichiometry, could be captured in solution ( Figure 4E ). This interaction could be readily detectable likely due to the block of subsequent conformational changes that requires the presence of lipid microenvironment, since the N-terminally exposed BAX is supposed to insert into the MOM. An ''embedded together'' model has been proposed to emphasize the importance of lipid in the activation of BAX that was facilitated by cardiolipin (Leber et al., 2007) . In addition, it was reported that unidentified MOM proteins assist tBID to activate BAX in the formation of lipidic pore (Schafer et al., 2009) . The identification of the canonical dimerization pocket as the second interaction site helps reconcile with previous mutagenesis study demonstrating the involvement of BH1 domain in the binding between BAX and BID (Wang et al., 1996) . BH1 domain is also required for BAK to interact with tBID. However, this interaction should be ''hitand-run'' in nature, since the same pocket is also utilized for homo-oligomerization. If BH3s continue to occupy the pocket, it is impossible for BAX or BAK to undergo homo-oligomerization. Indeed, it was reported that tBID was not coeluted with higher-ordered BAX oligomers by gel filtration upon TNFainduced apoptosis (Sundararajan and White, 2001 ). On the other hand, BH3s binds tightly to the pocket of antiapoptotic BCL-2 members such that antiapoptotic BCL-2 members do not homo-oligomerize ( Figure S11) . Moreover, the fact that BCL-2 was not coeluted with the higher-ordered BAX/BAK oligomers suggests that BCL-2 is unlikely to inhibit activated BAX/BAK directly ( Figure S11 ). Antiapoptotic BCL-2 members function like ''decoy'' death receptors that form inert stable complexes with BH3s but are incapable of assembling the death machinery that permeabilizes the MOM.
Since the a1 helix plays a pivotal role in initiating BAX activation, it is conceivable that inhibitors of BAX activation likely bind to the a1 helix to keep BAX inactive, exemplified by humanin (Guo et al., 2003) . On the contrary, VDAC2 binds to the dimerization pocket of BAK to keep BAK in check . In the absence of VDAC2, BAK exists as a monomer yet displays conformation-specific proteolysis sensitivity comparable to activated BAK . However, its full activation, i.e., homo-oligomerization, is still dependent on activator BH3s . By analogy, VDAC2 functions as a brake controlling the BAK-centered death machinery, whereas activator BH3s provide the driving force. Our recent genetic study provided in vivo evidence demonstrating a critical VDAC2-BAK axis in regulating the negative selection and survival of thymocytes (Ren et al., 2009) .
Both multidomain proapoptotic and antiapoptotic BCL-2 members reside at the ER to affect ER Ca 2+ store. Interestingly, BCL-2 and BCL-X L remain capable of regulating ER Ca 2+ even in Bax/Bak DKO cells (Oakes et al., 2005) . These data position antiapoptotic BCL-2 proteins downstream of BAX/BAK in maintaining ER Ca 2+ homeostasis, a hierarchy opposite to that for the control of mitochondrial apoptosis. We found that mitochondriabut not ER-targeted BAK is indispensable for ER stress-induced apoptosis in which BIM and PUMA function as sentinels interconnecting upstream death signals and downstream death program. BIM was induced by ER stress through CHOP-mediated transcriptional regulation and dephosphorylation-dependent stabilization (Puthalakath et al., 2007) , whereas how PUMA is regulated by ER stress remains unclear. The role of BID in ER stress-induced apoptosis was uncovered recently in
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Stepwise Activation of BAX/BAK by tBID/BIM/PUMA that BID was cleaved by caspase-2 upon ER stress (Upton et al., 2008) , which helps explain why double deficiency of Bim and Puma provides less apoptotic block than the deletion of Bax and Bak.
In summary, our data propose a stepwise model of BAX/BAK activation that integrates available structural and functional analyses and resolves a previously elusive hypothesis. Our study clearly demonstrates the essential axis of activator BH3s-BAX/ BAK in mitochondrial apoptosis.
EXPERIMENTAL PROCEDURES
Plasmid Construction and Retrovirus Production Indicated Bcl-2 members were cloned into pSG5 (Stratagene), pCDNA3 (Invitrogen), or the retroviral expression vector MSCV-IRES-GFP (pMIG) or MSCV-Puro (Clontech). All the constructs were confirmed by DNA sequencing. The production of retroviruses was described previously ).
Cell Culture and Viability Assay
The MEFs utilized were SV40 transformed. Reconstitution of BAX or BAK into DKO cell was achieved by retroviral transduction of BAX-IRES-GFP or BAK-IRES-GFP, followed by MoFlo (DakoCytomation) sorting for GFP-positive cells. Cell death was quantified by Annexin V-Cy3 (BioVision) staining, followed by flow cytometric analyses using a FACS Caliber (BD Biosciences) and CellQuest Pro software. P values for statistical analyses were obtained using Student's t test.
Mitochondria Isolation, Alkaline Extraction of BAX, Protein Crosslinking, and Gel Filtration Chromatography Mitochondria isolation and crosslinking of BAX were performed as described previously Kim et al., 2006) . The chromatographic step of Superdex 200 (HR 10/30, GE-Amersham) was performed on an automatic fast protein liquid chromatography (AKTApurifier, GE-Amersham). The column was equilibrated with 2% CHAPS buffer (2% CHAPS, 300 mM NaCl, 0.2 mM DTT, 20 mM HEPES [pH 7.5]) and calibrated with thyroglobulin (669 kD), ferritin (440 kD), catalase (232 kD), aldolase (158 kD), bovine serum albumin (66 kD), and cytochrome c (14 kD). Protein lysates (200 mg) were loaded onto the column, eluted at a flow rate of 0.3 ml/min. Fractions of 0.6 ml were collected, precipitated by trichloroacetic acid, and analyzed by 8%-16% SDS-PAGE (Bio-Rad). For alkaline extraction, mitochondria were resuspended in 0.1 M Na 2 CO 3 (pH 11.5) for 30 min on ice. Supernatant (alkali-sensitive) and pellet (alkali-resistant) fractions were separated by centrifugation at 75,000 rpm for 10 min at 4 C.
Immunoblot Analysis and Immunoprecipitation
Cell or mitochondrial lysates were resolved by NuPAGE (Invitrogen) gels and transferred onto PVDF (Immobilon-P, Millipore) followed by antibody detection using enhanced chemiluminescence method (Western Lightening, Perkin Elmer) and LAS-3000 Imaging system (FUJIFILM Life Science). In vitro transcription and translation (IVTT) reactions were performed using TNT T7 Quick Coupled Transcription/Translation System or Wheat Germ Extract System (Promega). IP of IVTT proteins was described previously (Kim et al., 2006) . To detect BAX or BAK homodimers, IP was performed using 0.2% NP40 isotonic buffer (0.2% NP40, 142.5 mM KCl, 5 mM MgCl 2 , 1 mM EGTA, 20 mM HEPES [pH 7.5]). To detect intramolecular interaction of BAX, IP was performed using 1% CHAPS buffer (1% CHAPS, 142.5 mM KCl, 2 mM CaCl 2 , 20 mM Tris-Cl [pH 7.4]). Anti-6A7 IP was performed using 1% CHAPS buffer.
Fluorescence Microscopy
Fluorescence images were acquired with a SPOT camera (Diagnostics Instruments) mounted on an Olympus IX51 microscope (Olympus).
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